Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 4/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | LATS1 | O95835 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21098921 | 1.00 | HTR2C (0.44) | HTR2CHTR2BHTR2ACCR1CCR5 | |
| SCHEMBL24454244 | 0.82 | PIM1 (0.43) | HTR2CHTR2BHTR2ACCR1CCR5 | |
| SCHEMBL24454076 | 0.82 | PIM1 (0.43) | HTR2CHTR2BHTR2ACCR1CCR5 | |
| SCHEMBL17884819 | 0.81 | HTR2C (0.47) | HTR2CHTR2BHTR2AGSK3BROCK2 | |
| SCHEMBL30609652 | 0.81 | HTR2C (0.47) | HTR2CHTR2BHTR2AGSK3BROCK2 | |
| SCHEMBL19709299 | 0.77 | ADRB1 (0.60) | HTR2CHTR2BHTR2A | |
| SCHEMBL2876435 | 0.77 | NCF1 (0.58) | CCR1CCR5CCR8NCF1 | |
| SCHEMBL21098425 | 0.77 | CYP2C19 (0.47) | HTR2CHTR2BHTR2AGSK3BPIM1 | |
| SCHEMBL21098430 | 0.77 | CYP2C19 (0.47) | HTR2CHTR2BHTR2AGSK3BPIM1 | |
| SCHEMBL26669762 | 0.77 | CYP2C19 (0.47) | HTR2CHTR2BHTR2AGSK3BPIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498715-B1 | ANTI-HCMV VIRUS COMPOUND | MEDSHINE DISCOVERY INC (CN) | 2021-06-09 | — | — | EP | disclosed |
| US-10851112-B2 | Anti-HCMV virus compound | MEDSHINE DISCOVERY INC. (CN) | 2020-12-01 | — | — | US | disclosed |
| US-20190202838-A1 | ANTI-HCMV VIRUS COMPOUND | PHAENO THERAPEUTICS CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| EP-3498715-A1 | ANTI-HCMV VIRUS COMPOUND | Medshine Discovery Inc. (CN) | 2019-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202838-A1 | ANTI-HCMV VIRUS COMPOUND | RPL35, RPL5, RPL17 | HTR2C 4587/4885HTR2B 4307/4885HTR2A 4512/4885 |
| US-10851112-B2 | Anti-HCMV virus compound | RPL35, RPL5, RPL17 | HTR2C 4587/4885HTR2B 4307/4885HTR2A 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.